Related references
Note: Only part of the references are listed.Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
A Perspective on the Evolution of Management of Cancer- and Chemotherapy-Induced Anemia
George M. Rodgers
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2012)
Projections of the Cost of Cancer Care in the United States: 2010-2020
Angela B. Mariotto et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Small Cell Lung Cancer
Gregory P. Kalemkerian et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2011)
Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003
Lauren E. Cipriano et al.
VALUE IN HEALTH (2011)
Chemotherapy and Survival Benefit in Elderly Patients With Advanced Non-Small-Cell Lung Cancer
Amy J. Davidoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated Extensive-Stage Small Cell Lung Cancer
Jingwei Jiang et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Multicenter Randomized Open-Label Phase III Study Comparing Efficacy, Safety, and Tolerability of Conventional Carboplatin Plus Etoposide Versus Dose-Intensified Carboplatin Plus Etoposide Plus Lenograstim in Small-Cell Lung Cancer in Extensive Disease Stage
David Felix Heigener et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2009)
Comparison of Hospitalization Risk and Associated Costs Among Patients Receiving Sargramostim, Filgrastim, and Pegfilgrastim for Chemotherapy-Induced Neutropenia
Mark L. Heaney et al.
CANCER (2009)
Risk of Hospitalization for Neutropenic Complications of Chemotherapy in Patients With Primary Solid Tumors Receiving Pegfilgrastim or Filgrastim Prophylaxis: A Retrospective Cohort Study
Derek Weycker et al.
CLINICAL THERAPEUTICS (2009)
Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124
Primo N. Lara et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer
Christopher G. Azzoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Costs of First-Line Doublet Chemotherapy and Lifetime Medical Care in Advanced Non-small-Cell Lung Cancer in the United States
Kathleen Lang et al.
VALUE IN HEALTH (2009)
Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis
Mei Sheng Duh et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC)
Josh J. Carlson et al.
LUNG CANCER (2008)
Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702
H. Okamoto et al.
BRITISH JOURNAL OF CANCER (2007)
Chemotherapy-induced nausea and vomiting-incidence and impact on patient quality of life at community oncology settings
Lorenzo Cohen et al.
SUPPORTIVE CARE IN CANCER (2007)
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer
Mary E. R. O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer
Dawn Hershman et al.
CANCER (2006)
Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database
Ramaswamy Govindan et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer
N Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based?: A meta-analysis of phase III randomized trials
JL Pujol et al.
LUNG CANCER (2006)
Taxanes as first-line therapy for advanced non-small cell lung cancer: A systematic review and practice guideline
Q Chu et al.
LUNG CANCER (2005)
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
HD Quan et al.
MEDICAL CARE (2005)
The economic burden of lung cancer and the associated costs of treatment failure in the United States
L Kutikova et al.
LUNG CANCER (2005)
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes
T Le Chevalier et al.
LUNG CANCER (2005)
Chemotherapy-induced nausea and vomiting in routine practice:: a European perspective
A Glaus et al.
SUPPORTIVE CARE IN CANCER (2004)
Estimating the cost of cancer: Results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000
S Chang et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: Evidence from Surveillance, Epidemiology and End Results-Medicare
SA Ramsey et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer
W Noda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: A population-based study
V Sundararajan et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis
C Mascaux et al.
LUNG CANCER (2000)
Share Paper
